References
Ferlay, J. S. I, Ervik, M, Diksh*t, R, Eser, S, Mathers, C., Rebelo, M. et al. Rebelo M et al. GLOBOCAN2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11, Lyon, France: International Agency for Research on Cancer. http://globocan.iarc.fr (2013).
Eisenhauer, E. A. Real-world evidence in the treatment of ovarian cancer. Ann. Oncol. 28, viii61–viii65 (2017).
CAS PubMed Google Scholar
Risch, H. A., McLaughlin, J. R., Cole, D. E., Rosen, B., Bradley, L., Kwan, E. et al. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am. J. Hum. Genet. 68, 700–710 (2001).
Alsop, K., Fereday, S., Meldrum, C., deFazio, A., Emmanuel, C., George, J. et al. BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. J. Clin. Oncol. 30, 2654–2663 (2012).
McPherson, K., Steel, C. M. & Dixon, J. M. ABC of breast diseases. Breast cancer-epidemiology, risk factors, and genetics. BMJ. 321, 624–628 (2000).
Easton, D., Ford, D. & Peto, J. Inherited susceptibility to breast cancer. Cancer Surv. 18, 95–113 (1993).
CAS PubMed Google Scholar
Oesterreich, S. & Fuqua, S. A. Tumor suppressor genes in breast cancer. Endocr. Relat. Cancer. 6, 405–419 (1999).
CAS PubMed Google Scholar
Lakhani, S. R., Reis-Filho, J. S., Fulford, L., Penault-Llorca, F., van der Vijver, M., Parry, S. et al. Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype. Clin. Cancer Res. 11, 5175–5180 (2005).
CAS PubMed Google Scholar
Bryant, H. E., Schultz, N., Thomas, H. D., Parker, K. M., Flower, D., Lopez, E. et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434, 913–917 (2005).
CAS PubMed Google Scholar
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B. et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434, 917–921 (2005).
CAS PubMed Google Scholar
Murai, J., Huang S-yN, Das, B. B., Renaud, A., Zhang, Y., Doroshow, J. H. et al. Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors. Cancer Res. 72, 5588–5599 (2012).
Polak, P., Kim, J., Braunstein, L. Z., Karlic, R., Haradhavala, N. J., Tiao, G. et al. A mutational signature reveals alterations underlying deficient hom*ologous recombination repair in breast cancer. Nat. Genet. 49, 1476 (2017).
CAS PubMed Google Scholar
FDA. Lynparza (olaparib) tablets, for oral use: prescribing information. https://www.fda.gov/drugs/fda-approved-olaparib-lynparza-astrazeneca-pharmaceuticals-lp-maintenance-treatment-adult-patients (2018).
Mirza, M. R., Monk, B. J., Herrstedt, J., Oza, A. M., Mahner, S., Redondo, A. et al. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N. Engl. J. Med. 375, 2154–2164 (2016).
CAS PubMed Google Scholar
Coleman, R. L., Oza, A. M., Lorusso, D., Aghajanian, C., Oaknin, A., Dean, A. et al. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet 390, 1949–1961 (2017).
CAS Google Scholar
Moore, K., Colombo, N., Scambia, G., Kim, B.-G., Oaknin, A., Friedlander, M. et al. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N. Engl. J. Med. 379, 2495–2505 (2018).
CAS PubMed Google Scholar
Robson, M., Im, S.-A., Senkus, E., Xu, B., Domchek, S. M., Masuda, N. et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N. Engl. J. Med. 377, 523–533 (2017).
CAS PubMed Google Scholar
Barber, L. J., Sandhu, S., Chen, L., Campbell, J., Kozarewa, I., Fenwick, K. et al. Secondary mutations in BRCA2 associated with clinical resistance to a PARP inhibitor. J. Pathol. 229, 422–429 (2013).
CAS PubMed Google Scholar
Makvandi, M., Xu, K., Lieberman, B. P., Anderson, R.-C., Effron, S. S., Winters, H. D. et al. A radiotracer strategy to quantify PARP-1 expression in vivo provides a biomarker that can enable patient selection for PARP Inhibitor Therapy. Cancer Res. 76, 4516 (2016).
Ray Chaudhuri, A., Callen, E., Ding, X., Gogola, E., Duarte, A. A., Lee, J.-E. et al. Replication fork stability confers chemoresistance in BRCA-deficient cells. Nature 535, 382 (2016).
Issaeva, N., Thomas, H. D., Djureinovic, T., Jaspers, J. E., Stoimenov, I., Kyle, S. et al. 6-thioguanine selectively kills BRCA2-defective tumors and overcomes PARP inhibitor resistance. Cancer Res. 70, 6268–6276 (2010).
Coulthard, S. & Hogarth, L. The thiopurines: An update. Investigational New Drugs. 23, 523–532 (2005).
CAS PubMed Google Scholar
Swann, P. F., Waters, T. R., Moulton, D. C., Xu, Y. Z., Zheng, Q., Edwards, M. et al. Role of postreplicative DNA mismatch repair in the cytotoxic action of thioguanine. Science 273, 1109–1111 (1996).
CAS PubMed Google Scholar
Griffin, S., Branch, P., Xu, Y. Z. & Karran, P. DNA mismatch binding and incision at modified guanine bases by extracts of mammalian cells: implications for tolerance to DNA methylation damage. Biochemistry 33, 4787–4793 (1994).
CAS PubMed Google Scholar
Waters, T. R. & Swann, P. F. Cytotoxic mechanism of 6-thioguanine: hMutSalpha, the human mismatch binding heterodimer, binds to DNA containing S6-methylthioguanine. Biochemistry. 36, 2501–2506 (1997).
CAS PubMed Google Scholar
Yan, T., Berry, S. E., Desai, A. B. & Kinsella, T. J. DNA mismatch repair (MMR) mediates 6-thioguanine genotoxicity by introducing single-strand breaks to signal a G2-M arrest in MMR-proficient RKO cells. Clin. Cancer Res. 9, 2327–2334 (2003).
CAS PubMed Google Scholar
Lennard, L. The clinical pharmacology of 6-mercaptopurine. Eur. J. Clin. Pharmacol. 43, 329–339 (1992).
CAS PubMed Google Scholar
Relling, M. V., Hanco*ck, M. L., Rivera, G. K., Sandlund, J. T., Ribeiro, R. C., Krynetski, E. Y. et al. Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus. J Natl Cancer Inst. 91, 2001–2008 (1999).
CAS PubMed Google Scholar
Dean L. Mercaptopurine Therapy and TPMT Genotype (eds Pratt V., McLeod H., Dean L., Malheiro A. & Rubinstein W.). (Medical Genetics Summaries, Bethesda, MD, 2012).
Bokkerink, J. P., De Abreu, R. A., Bakker, M. A., Hulscher, T. W., van Baal, J. M., Schretlen, E. D. et al. Effects of methotrexate on purine and pyrimidine metabolism and cell-kinetic parameters in human malignant lymphoblasts of different lineages. Biochem. Pharmacol. 37, 2329–2338 (1988).
CAS PubMed Google Scholar
Martin, S. A., McCarthy, A., Barber, L. J., Burgess, D. J., Parry, S., Lord, C. J. et al. Methotrexate induces oxidative DNA damage and is selectively lethal to tumour cells with defects in the DNA mismatch repair gene MSH2. EMBO Mol. Med. 1, 323–337 (2009).
Nicum, S., Roberts, C., Boyle, L., Kopijasz, S., Gourley, C., Hall, M. et al. A phase II clinical trial of 6-mercaptopurine (6MP) and methotrexate in patients with BRCA defective tumours: a study protocol. BMC Cancer 14, 983 (2014).
Jung, S. H., Carey, M. & Kim, K. M. Graphical search for two-stage designs for phase II clinical trials. Control Clin. Trials. 22, 367–372 (2001).
CAS PubMed Google Scholar
Jung, S. H., Lee, T., Kim, K. & George, S. L. Admissible two-stage designs for phase II cancer clinical trials. Stat Med. 23, 561–569 (2004).
Hawwa, A. F., Millership, J. S., Collier, P. S. & McElnay, J. C. Development and validation of an HPLC method for the rapid and simultaneous determination of 6-mercaptopurine and four of its metabolites in plasma and red blood cells. J. Pharm. Biomed. Anal. 49, 401–409 (2009).
CAS PubMed Google Scholar
Kaufman, B., Shapira-Frommer, R., Schmutzler, R. K., Audeh, M. W., Friedlander, M., Balmana, J. et al. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. J. Clin. Oncol. 33, 244–250 (2015).
CAS PubMed Google Scholar
McNeish, I. A., Ledermann, J. A., Webber, L., James, L., Kaye, S. B., Hall, M. et al. A randomised, placebo-controlled trial of weekly pacl*taxel and saracatinib (AZD0530) in platinum-resistant ovarian, fallopian tube or primary peritoneal cancerdagger. Ann. Oncol. 25, 1988–1995 (2014).
CAS PubMed Google Scholar
Tan, D. S., Yap, T. A., Hutka, M., Roxburgh, P., Ang, J., Banerjee, S. et al. Implications of BRCA1 and BRCA2 mutations for the efficacy of pacl*taxel monotherapy in advanced ovarian cancer. Eu.r J. Cancer 49, 1246–1253 (2013).
CAS Google Scholar
Kaye, S. B., Lubinski, J., Matulonis, U., Ang, J. E., Gourley, C., Karlan, B. Y. et al. Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer. J. Clin. Oncol. 30, 372–379 (2012).
CAS PubMed Google Scholar
Lilleyman, J. S. & Lennard, L. Mercaptopurine metabolism and risk of relapse in childhood lymphoblastic leukaemia. Lancet. 343, 1188–1190 (1994).
CAS PubMed Google Scholar
Hawwa, A. F., Collier, P. S., Millership, J. S., McCarthy, A., Dempsey, S., Cairns, C. et al. Population pharmaco*kinetic and pharmacogenetic analysis of 6-mercaptopurine in paediatric patients with acute lymphoblastic leukaemia. Br. J. Clin. Pharmacol. 66, 826–837 (2008).
Cheok, M. H. & Evans, W. E. Acute lymphoblastic leukaemia: a model for the pharmacogenomics of cancer therapy. Nat Rev Cancer. 6, 117–129 (2006).
CAS PubMed Google Scholar
Colombel, J. F., Ferrari, N., Debuysere, H., Marteau, P., Gendre, J. P., Bonaz, B. et al. Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn’s disease and severe myelosuppression during azathioprine therapy. Gastroenterology. 118, 1025–1030 (2000).
CAS PubMed Google Scholar
Lennard, L., Welch, J. & Lilleyman, J. S. Mercaptopurine in childhood leukaemia: the effects of dose escalation on thioguanine nucleotide metabolites. Br. J. Clin. Pharmacol. 42, 525–527 (1996).
Dervieux, T., Brenner, T. L., Hon, Y. Y., Zhou, Y., Hanco*ck, M. L., Sandlund, J. T. et al. De novo purine synthesis inhibition and antileukemic effects of mercaptopurine alone or in combination with methotrexate in vivo. Blood. 100, 1240–1247 (2002).
CAS PubMed Google Scholar
McAlpine, J. N., Porter, H., Kobel, M., Nelson, B. H., Prentice, L. M., Kalloger, S. E. et al. BRCA1 and BRCA2 mutations correlate with TP53 abnormalities and presence of immune cell infiltrates in ovarian high-grade serous carcinoma. Mod. Pathol. 25, 740–750 (2012).
CAS PubMed Google Scholar
Strickland, K. C., Howitt, B. E., Shukla, S. A., Rodig, S., Ritterhouse, L. L., Liu, J. F. et al. Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer. Oncotarget 7, 13587–13598 (2016).
Nolan, E., Savas, P., Policheni, A. N., Darcy, P. K., Vaillant, F., Mintoff, C. P., et al. Combined immune checkpoint blockade as a therapeutic strategy for BRCA1-mutated breast cancer. Sci. Transl. Med. 9, pii: eaal4922 (2017).
